Neoplasms, Lung
19
2
3
9
Key Insights
Highlights
Success Rate
69% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
21.1%
4 terminated out of 19 trials
69.2%
-17.3% vs benchmark
11%
2 trials in Phase 3/4
33%
3 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (19)
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Precision Lung Cancer Survivorship Care Intervention
Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma
Study of ESG401 in Adults With Solid Tumors
Remote Monitoring of Lung Cancer Patient-Reported Outcomes Using Moovcare®
MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
A Phase I Study of iPS Cell Generation From Patients With COPD
Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer
NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung
NEUWAVE Flexible Probe Study #2
The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
Incidence of Postthoracotomy Pain Following General Anesthesia: A Comparison Between TIVA and Inhalation Anesthesia
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.